Redeye: Saniona - PWS is (ultra-) orphan!

In this update, we will do a deep-dive of the two programs that have advanced in the last couple of months, i.e., the Ataxia program and Tesomet within eating disorders. The Ataxia program still represents a small share of our total value whereas we see the Tesomet program within eating disorders to have the largest potential for Saniona.

Read more in the Research Update by Anders Hedlund: https://goo.gl/RysUT7

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/

Om oss

Saniona är ett forsknings- och utvecklingsbolag som bedriver läkemedelsutveckling av preparat som ska användas till sjukdomar i centrala nervsystemet, autoimmuna sjukdomar och behandling av smärta.

Prenumerera